


RSC Drug Discovery

Edited by Ben M. Dunn

# Proteinases as Drug Targets



RSC Publishing

# *Proteinases as Drug Targets*

Edited by

**Ben Dunn**

*Department of Biochemistry and Molecular Biology, University of Florida,  
Gainesville, FL, USA*



RSC Publishing

RSC Drug Discovery Series No. 18

ISBN: 978-1-84973-049-5

ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© Royal Society of Chemistry 2012

*All rights reserved*

*Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.*

The RSC is not responsible for individual opinions expressed in this work.

Published by The Royal Society of Chemistry,  
Thomas Graham House, Science Park, Milton Road,  
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our web site at [www.rsc.org](http://www.rsc.org)

## Proteinases as Drug Targets

## RSC Drug Discovery Series

### *Editor-in-Chief:*

Professor David Thurston, *London School of Pharmacy, UK*

### *Series Editors:*

Dr David Fox, *Pfizer Global Research and Development, Sandwich, UK*

Professor Salvatore Guccione, *University of Catania, Italy*

Professor Ana Martinez, *Instituto de Química Medica-CSIC, Spain*

Dr David Rotella, *Montclair State University, USA*

### *Advisor to the Board:*

Professor Robin Ganellin, *University College London, UK*

### *Titles in the Series:*

- 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET
- 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism
- 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies
- 4: Accounts in Drug Discovery: Case Studies in Medicinal Chemistry
- 5: New Frontiers in Chemical Biology: Enabling Drug Discovery
- 6: Animal Models for Neurodegenerative Disease
- 7: Neurodegeneration: Metallostasis and Proteostasis
- 8: G Protein-Coupled Receptors: From Structure to Function
- 9: Pharmaceutical Process Development: Current Chemical and Engineering Challenges
- 10: Extracellular and Intracellular Signaling
- 11: New Synthetic Technologies in Medicinal Chemistry
- 12: New Horizons in Predictive Toxicology: Current Status and Application
- 13: Drug Design Strategies: Quantitative Approaches
- 14: Neglected Diseases and Drug Discovery
- 15: Biomedical Imaging: The Chemistry of Labels, Probes and Contrast Agents
- 16: Pharmaceutical Salts and Cocrystals
- 17: Polyamine Drug Discovery
- 18: Proteinases as Drug Targets

### *How to obtain future titles on publication:*

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

### *For further information please contact:*

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247, Email: [books@rsc.org](mailto:books@rsc.org)

Visit our website at <http://www.rsc.org/Shop/Books/>

# Preface

Proteolytic enzymes play important roles in many metabolic processes in the human body. In recent years, the roles of proteinases in many cellular processes have been revealed, thus placing this type of enzyme into the forefront in efforts to control normal and abnormal physiological function. In the chapters that follow, the terms proteolytic enzyme, protease, and peptidase will be used interchangeably to mean the same thing: a protein with the ability to catalyze the extremely rapid cleavage of peptide bonds of other proteins with sometimes remarkable specificity for the peptide bond cleaved and sometimes with more general cleavage of multiple peptide bonds.

In the last few decades inhibitors of proteolytic enzymes have been discovered that are valuable in treating some human conditions. Among the first of these was the development of inhibitors of angiotensin converting enzyme, or ACE, including Captopril<sup>®</sup>. By blocking the conversion of angiotensin I to angiotensin II, ACE inhibitors provide a mechanism to lower blood pressure, as angiotensin II has a strong pressor activity. In the same pathway, scientists have long sought inhibitors of the first enzyme, renin, with many starts and stops. Recently, orally available inhibitors have been developed that show promise in controlling the start of the angiotensin cascade.

At the end of the 1980's and into the decade of the 1990's, a major focus of research was on developing compounds that would block the replication and spread of the Human Immunodeficiency Virus (HIV). It was recognized that the virus contained a segment of nucleotides coding for a protein that had sequence identity to one half of an aspartic proteinase, such as pepsin or cathepsin D. The discovery of HIV proteinase led to the eventual development of Saquinavir, Indinavir, and Ritonavir which provided a second set of drugs to combine with inhibitors of the viral reverse transcriptase. After considerable effort and clinical trials, the combination therapy for treatment of HIV



infection was optimized for human use. This has been followed by seven other compounds that inhibit the viral protease with increasing potency and with improved efficacy versus the drug-resistant forms of HIV that develop upon prolonged use of the older inhibitors. It should be appreciated that the earlier work on development of renin inhibitors noted in the above paragraph was vital in the rapid development of the HIV protease inhibitors.

This book collects chapters from scientists who are continuing the effort to identify new proteolytic enzymes that may serve as targets for new drug discovery. Eleven chapters provide details on recent studies of important enzymes.

The enzymes known as dipeptidyl peptidases are involved in many different processes such as "...liver disease, obesity, type II diabetes, arthritis, inflammatory bowel disease and cancer", quoting from the introduction to the chapter from Cathy Abbott. In addition, effects on innate immunity and the processing of a variety of peptide hormones can be mediated by members of this family. The chapter from Mark Gorrell and colleagues continues this discussion by focusing on dipeptidyl peptidase IV (DPPIV), which is a new target for drug discovery in diabetes. DPPIV has generated a lot of excitement in the research community that studies diabetes and drugs are beginning to reach the marketplace.

Vivian Hook has contributed a chapter that discusses the role of the cysteine proteinase B in Alzheimer's Disease. While considerable effort has been underway on other enzymes that are involved in cleavage of the beta amyloid precursor protein to produce the fragments that form plaques in patient's brains, Dr. Hook points out data that indicates that cathepsin B may play an important role there as well.

The chapter contributed by Pampalakis and Sotiropoulou discusses the kallakreins, including plasma kallakrein and tissue kallakreins. The former is involved in the release of bradykinin from High Molecular Weight Kininogen and the latter, also known as tissue kallakrien-related peptidases (KLKs), is a group of serine proteases that involved in release Lys-bradykinin from Low Molecular Weight Kininogen. In addition, the KLKs are involved in tissue-specific cascades to control physiological functions. As such they are excellent targets for pharmacological intervention.

Christoph Becker-Pauly discusses meprins  $\alpha$  and  $\beta$  and the multitude of pathophysiological roles they play in human health and disease. These enzymes are representatives of the metallo-peptidase family and expand the coverage of this book. There is a large family of related enzymes in this group and they play different roles in different tissues. Another metallo-peptidase is glutamate carboxypeptidase II, discussed by Jan Konvalinka and colleagues. This enzyme is overexpressed in metastatic prostate cancer and could present a new target for drug discovery.

Two chapters discuss aspects of proteins known as inactive serine proteases, especially those from a significant human parasite, the skin mite *Sarcoptes scabiei*. This mite can cause devastating disease in severe cases and little is known about effect therapies. Katja Fischer focuses on the role of the title

proteins in the evasion of the complement system, while the chapter from Ashley Buckle discusses the structural reasons for the lack of activity in the inactive serine proteases.

There are a large number of parasitic organisms that live by feeding on the blood of their hosts. Alex Loukas considers the proteases from another major human pathogen, the hookworm. The chapter compiles information on a wide variety of proteolytic enzymes from the hookworm and discusses both vaccine strategies as well as drug development for control of this pest.

The book concludes with two chapters that focus on enzymes from the malaria parasite, *Plasmodium falciparum*. These continue the theme developed by Alex Loukas in his discussion of the hookworm and feeding upon blood. First, Sheena McGowan discusses the neutral aminopeptidases of the malaria parasite and the great potential for development of anti-malarial agents through work that has been accomplished to determine the three dimensional structure. Finally, the last chapter by this author discusses the members of the aspartic proteinase family present in the malaria parasite and, where possible, details of the structure and properties of the enzymes are presented. A discussion of the development of inhibitors of these enzymes is presented.

Ben M. Dunn  
Gainesville, Florida



# Contents

<b>Chapter 1</b>	<b>Dipeptidyl Peptidases: Substrates and Therapeutic Targeting in Human Health and Disease</b>	<b>1</b>
	<i>Claire H. Wilson and Catherine A. Abbott</i>	
1.1	Introduction	1
1.2	Post-Proline-Cleaving Enzymes	2
1.3	DP4-Like Gene Family and Related Enzymes	3
1.3.1	Homology and Gene Structure	6
1.4	Protease Members of the DP4-Like Gene Family	6
1.4.1	DP4 and FAP: Extracellular Proteins	6
1.4.2	DP8 and DP9: Intracellular Proteins	10
1.5	Protein Structure, Active Site Entry, and Substrate Specificity	13
1.6	DP Substrates: Biological Relevance to Human Health and Disease	16
1.6.1	Glucose Homeostasis and Nutrient Metabolism	16
1.6.2	Cardiovascular Effects	19
1.6.3	Nociception and Neuropsychiatric Disorders	20
1.6.4	Immune System and Disorders	21
1.6.5	Tissue Repair and Cancer	22
1.7	Therapeutic Targeting of the DPs	23
1.7.1	Targeting Enzymatic Function	24
1.7.2	Targeting Non-Enzymatic Function	27
1.8	Conclusion	28
	References	29

<b>Chapter 2</b>	<b>The Metalloproteases Meprin <math>\alpha</math> and <math>\beta</math>: Pathophysiological Roles in Inflammation, Cardiovascular Disease, Cancer, and Fibrosis</b>	<b>44</b>
	<i>Christoph Becker-Pauly</i>	
2.1	Introduction	44
2.1.1	Structural Features of Meprins	46
2.1.2	Activation of Meprins	46
2.1.3	Substrate and Cleavage Specificity of Meprin $\alpha$ and $\beta$	46
2.2	Pathophysiological Relevance of Meprins	49
2.2.1	Inflammatory Disease	49
2.2.2	Angiogenesis and Cancer	51
2.2.3	Fibrosis	53
2.3	Inhibitors of Meprin $\alpha$ and $\beta$	55
	References	58
<b>Chapter 3</b>	<b>Glutamate Carboxypeptidase II as a Therapeutic Target</b>	<b>62</b>
	<i>Klára Hlouchová, Cyril Bařinka and Jan Konvalinka</i>	
3.1	Introduction	62
3.2	Gene and mRNA	63
3.2.1	GCPII mRNA	64
3.3	GCPII Localization	64
3.3.1	Protein Expression in Human and Animal Tissues	65
3.3.2	Cellular Localization	69
3.4	GCPII Biology	69
3.5	GCPII Homologs	70
3.5.1	Human Paralogs	70
3.6	Structure and Enzymology	71
3.6.1	Enzymology	71
3.6.2	Structure	72
3.7	GCPII Inhibitors and Ligands	76
3.7.1	Low-Molecular-Weight Ligands	76
3.7.2	Macromolecules	81
3.8	Applications	81
3.8.1	Experimental Anti-Neurodegeneration Therapy	81
3.8.2	Cancer	83
3.9	Conclusions and Future Perspectives	85
	References	86

<b>Chapter 4</b>	<b>The Role of Proteolytically Inactive Serine Proteases from <i>Sarcoptes scabiei</i> in Complement Evasion</b>	<b>96</b>
	<i>Simone Reynolds and Katja Fischer</i>	
4.1	Scabies and Associated Bacterial Skin Infections	96
4.2	Host Immune Response to Scabies Infection	98
4.3	<i>Sarcoptes scabiei</i> Gene Discovery	99
4.4	Scabies Mite Inactive Protease Paralogues (SMIPP-Ss)	101
4.4.1	Scabies Mite Inactive Protease Paralogues Inhibit Complement	102
4.4.2	Complement-Subversion Strategies in Other Parasitic Organisms	104
4.5	Inactive Proteases in Other Organisms	107
4.5.1	Functions of Inactive Proteases	108
4.5.2	Mode of Action of Inactive Enzymes	110
4.6	Conclusion	111
	Acknowledgment	112
	References	112
<b>Chapter 5</b>	<b>Targeting Dipeptidyl Peptidase-4 (DPP-4) and Fibroblast Activation Protein (FAP) for Diabetes and Cancer Therapy</b>	<b>118</b>
	<i>F. M. Keane, S. Chowdhury, T.-W. Yao, N. A. Nadvi, M. G. Gall, Y. Chen, B. Osborne, A. J. V. Ribeiro, W. B. Church, G. W. McCaughan, M. D. Gorrell and D. M. T. Yu</i>	
5.1	Introduction	118
5.2	DPP-4	119
5.2.1	Functions of DPP-4	119
5.2.2	Distribution of DPP-4	120
5.2.3	Structure of DPP-4	121
5.2.4	Substrates of DPP-4	122
5.2.5	DPP-4 Inhibitors in Disease Therapy	124
5.3	FAP	129
5.3.1	Functions of FAP	129
5.3.2	Distribution of FAP	130
5.3.3	Structure of FAP	130
5.3.4	Substrates of FAP	132
5.3.5	Targeting FAP for Cancer Therapy	132
5.4	Recent Developments in the DPP-4 Protease Family	135
5.5	Conclusion	136
	Acknowledgments	136
	References	136

<b>Chapter 6</b>	<b>Discovery of the Cysteine Protease Cathepsin B as a Drug Target for Alzheimer's Disease</b>	<b>145</b>
	<i>Vivian Hook, Mark Kindy and Gregory Hook</i>	
6.1	Introduction: Alzheimer's Disease and $\beta$ -Amyloid	145
6.2	Strategies to Identify Protease(s) Cleaving at the Wild-Type $\beta$ -Secretase Site of APP	147
6.2.1	Specificity of Peptide Substrate Cleavage by Proteases	149
6.2.2	Design of Wild-Type $\beta$ -Secretase Peptide Substrate, Based on the P2-P1 Residues at the Wild-Type $\beta$ -Secretase Site of APP	149
6.3	Cathepsin B is Identified as a Candidate $\beta$ -Secretase in Secretory Vesicles for Production of A $\beta$ Peptides	150
6.3.1	Regulated Secretory Vesicles Produce the Majority of Secreted A $\beta$	150
6.3.2	Wild-Type $\beta$ -Secretase Substrate Leads to Identification of Cathepsin B in A $\beta$ -Producing Secretory Vesicles	151
6.3.3	Distinct Cleavage Specificity of Cathepsin B for the Wild-Type $\beta$ -Secretase Site of APP, But Not the Swedish Mutant $\beta$ -Secretase Site	151
6.4	Inhibition or Knockout of Cathepsin B Reduces A $\beta$ Production	154
6.4.1	Inhibition of Cathepsin B Reduces A $\beta$ in Regulated Secretory Vesicles of Neurons	154
6.4.2	Cathepsin B Inhibitor Treatment of Guinea Pigs, Expressing Human Wild-Type APP, Reduces Brain A $\beta$	154
6.4.3	Inhibition of Cathepsin B Reduces Brain A $\beta$ and Improves Memory Deficits in a Mouse Model Expressing Human APP with the Wild-Type $\beta$ -Secretase Site, But Not in Mice Expressing APP with the Swedish Mutant Site	154
6.4.4	Knockout of the Cathepsin B Gene Results in Reduction in Brain A $\beta$ in Mice Expressing APP with the Wild-Type $\beta$ -Secretase Site, But Not in Mice Expressing the Swedish Mutant Site of APP	157
6.4.5	Cathepsin B Degradation of A $\beta$ is Not Significant <i>In Vivo</i>	161



6.5	Hypothesis that Cathepsin B and BACE1 Participate as Dual $\beta$ -Secretases for A $\beta$ Production	162
6.5.1	BACE1 Prefers to Cleave the Swedish Mutant $\beta$ -Secretase Site, Rather Than the Wild-Type $\beta$ -Secretase Site of APP	162
6.5.2	BACE1 Knockout in Swedish APP-Expressing Mice	163
6.5.3	$\beta$ -Secretase Activity in BACE1 Knockout Mice	163
6.5.4	A $\beta$ Production and Secretion in Neurons of BACE1 Knockout Mice	164
6.5.5	BACE1 and A $\beta$ Production in Mice Expressing Normal Compared to Very High Expression Levels of APP: Relationship to AD Patients Expressing Physiological Levels of APP	164
6.6	Cathepsin B Inhibitors as Potential Therapeutic Agents for the Majority of AD Patients Expressing Wild-Type APP	165
	Acknowledgments	165
	References	165

<b>Chapter 7</b>	<b><i>Plasmodium falciparum</i> Neutral Aminopeptidases: Development of Novel Anti-Malarials by Understanding Enzyme Structure</b>	<b>169</b>
	<i>Donald Gardiner, John Dalton and Sheena McGowan</i>	
7.1	Introduction	169
7.1.1	Falciparum Malaria: The Health Burden	169
7.1.2	A Continuing Need for New Targets for Novel Anti-Malarials	170
7.1.3	<i>Pf</i> Neutral Aminopeptidases as New Drug Targets	172
7.2	<i>Pf</i> Neutral Aminopeptidases	173
7.2.1	<i>Pf</i> A-M1 Alanyl Aminopeptidase	173
7.2.2	<i>Pf</i> A-M17 Leucyl Aminopeptidase	176
7.3	Structure-Activity-Relationship Data and Drug Design	180
7.3.1	Current Inhibitors of the Neutral Aminopeptidases	180
7.3.2	Structure-Activity Relationships and Future Rational Drug Design	182
7.4	Conclusions	183
	Acknowledgments	183
	References	183



<b>Chapter 8</b>	<b>Blood-Feeding Human Hookworm Proteases</b>	<b>186</b>
	<i>A. Loukas, N. Ranjit, D. A. Pickering and M. S. Pearson</i>	
8.1	Introduction	186
8.2	Proteases of Adult-Stage Hookworms	187
8.2.1	Aspartic Proteases	189
8.2.2	Cysteine Proteases	191
8.2.3	Metalloproteases	192
8.2.4	Aminopeptidases and Exopeptidases	193
8.3	Proteases of Larval-Stage Hookworms	194
8.4	Concluding Remarks	195
	Acknowledgments	195
	References	195
<b>Chapter 9</b>	<b>Pharmacological Targeting of Human Tissue Kallikrein-Related Peptidases</b>	<b>199</b>
	<i>Georgios Pampalakis and Georgia Sotiropoulou</i>	
9.1	Introduction	199
9.1.1	Human Tissue Kallikrein-Related Peptidases	199
9.1.2	Why Should We Target KLKs? Association of KLK with Disease	200
9.1.3	Structure of KLKs	203
9.1.4	Identification of Substrates and Endogenous Inhibitors	204
9.2	Peptide Modulators	205
9.2.1	Synthetic LEKTI Domains	205
9.2.2	Cyclic Peptide Inhibitors	205
9.2.3	Peptide Activators of KLKs	205
9.2.4	Depsipeptides	207
9.3	Inhibitors Designed Based on Bioscaffolds	208
9.3.1	Engineered Sunflower Trypsin Inhibitor (SFTI)	208
9.3.2	Mutant Serpins	208
9.4	Synthetic Inhibitors Based on Modified Peptide-Substrates or Small Molecules	209
9.4.1	KLK1 Inhibitors	212
9.4.2	KLK3/PSA Inhibitors	213
9.4.3	Imaging Based on KLK3/PSA	216
9.4.4	KLK7 Inhibitors	217
9.4.5	General Modulators of KLKs	218
9.5	Antibody-Derived Inhibitors	219
9.5.1	Potential of Antibody Phage Display Strategy	219
9.5.2	Antibodies Directed Against KLKs	219
9.6	Future Directions	221
	References	222

<b>Chapter 10</b>	<b>Structural Mechanisms of Inactivation in Proteolytically Inactive Serine Proteases from <i>Sarcoptes scabiei</i></b>	<b>229</b>
	<i>Katja Fischer, James A. Irving, Robert Pike and Ashley M. Buckle</i>	
10.1	Scabies	229
10.1.1	Scabies Mite Inactivated Protease Paralogues (SMIPPs)	230
10.2	Crystal Structural Analysis of SMIPPs	230
10.2.1	SMIPPs Adopt the Chymotrypsin-Like Serine Protease Fold	230
10.2.2	Structural Diversity Within the Active Site and Throughout the Molecules	232
10.3	Peptide Phage Display Screening Does Not Identify Binding Partners	233
10.4	Restoration of the Catalytic Triad by Mutagenesis Does Not Rescue Protease Activity	234
10.5	Phylogenetic Analysis of the SMIPP Family	234
10.6	SMIPPs Do Not Function by Competing for Substrates with Host Proteases That Play a Role in Host Defense Mechanisms	235
10.6.1	Putative Alternative Binding Sites	237
10.6.2	Sequence Conservation in the SMIPP Family	237
10.7	Conclusions	240
	Acknowledgments	240
	References	240
<b>Chapter 11</b>	<b>The Aspartic Proteinases from the Malaria Parasite: Structure and Function of the Plasmepsins</b>	<b>242</b>
	<i>Ben M. Dunn</i>	
11.1	Introduction	242
11.1.1	Tropical Diseases and the Need for Drug Discovery	242
11.2	Malaria	244
11.2.1	Plasmepsins as Targets for Drug Discovery Against Malaria	245
11.2.2	Plasmepsin Gene Family in the Malaria Parasite	245
11.3	Digestive Vacuole Enzymes	246
11.3.1	Plasmepsin I	246
11.3.2	Plasmepsin II	248
11.3.3	HAP, the Histo-Aspartic Plasmepsin	252
11.3.4	Plasmepsin IV	253

11.4	Non-Digestive Vacuole Plasmepsins	255
11.4.1	Plasmepsin V	256
11.4.2	Plasmepsin IX and Plasmepsin X	257
11.5	Inhibitor Development	258
11.5.1	HIV PR Inhibitors and Malaria	262
11.6	Summary	263
	Acknowledgments	263
	References	263

**Subject Index****270**

## CHAPTER 1

# ***Dipeptidyl Peptidases: Substrates and Therapeutic Targeting in Human Health and Disease***

CLAIRE H. WILSON AND CATHERINE A. ABBOTT

School of Biological Sciences, Flinders University, GPO BOX 2100,  
Adelaide 5001, South Australia, Australia

## **1.1 Introduction**

Dipeptidyl peptidase 4 (DP4), fibroblast activation protein (FAP), DP8, and DP9 are the enzymatic members of the serine protease S9b DP4-like gene family. One of the most important features of the DPs is their ability to preferentially cleave the N-terminal post-prolyl bond of regulatory peptides and small protein substrates. DP4 proteolysis results in the inactivation, activation, or alteration of its substrates function via changes in receptor selectivity; thus DP4 plays an important role in regulating biological function. Together, DP4 and FAP have been implicated in a number of diseases including liver disease, obesity, type II diabetes, arthritis, inflammatory bowel disease and cancer. Recently, evidence has emerged to implicate both DP8 and DP9 in innate immunity, and DP8/9 *in vitro* cleavage of well-known DP4 substrates, including neuropeptide Y (NPY), glucagon-like peptide (GLP)-1, and a number of chemokines, has been demonstrated. Despite this, the true pathophysiological roles of DP8/9 and their involvement within human biology and disease are still to be elucidated. Identification of the *in vivo* substrate repertoire of each DP will be an important step toward elucidating the biochemical pathways in which each protease is involved. This will allow us to unravel further the roles that the

---

RSC Drug Discovery Series No. 18

Proteinases as Drug Targets

Edited by Ben Dunn

© Royal Society of Chemistry 2012

Published by the Royal Society of Chemistry, [www.rsc.org](http://www.rsc.org)